The target of this therapy is the molecular docking process that initiates the inhibition of proinflammatory cytokines such as cyclooxygenase-2 (COX-2), tumor necrosis factor alpha (TNF-a) and interleukin-1b (IL-1b) that reduce cardiovascular risk in rheumatoid arthritis. Here, TNF is linked to rheumatoid arthritis.